Biotech | August 14, 2021
Bharat Biotech’s first nasal vaccine gets approval for Phase 2 trials
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Substantial reduction in losses
The company has strong product launches both in India and overseas
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Subscribe To Our Newsletter & Stay Updated
